DE60226612D1 - Autologe t-zell-vakzinmaterialien und verfahren - Google Patents

Autologe t-zell-vakzinmaterialien und verfahren

Info

Publication number
DE60226612D1
DE60226612D1 DE60226612T DE60226612T DE60226612D1 DE 60226612 D1 DE60226612 D1 DE 60226612D1 DE 60226612 T DE60226612 T DE 60226612T DE 60226612 T DE60226612 T DE 60226612T DE 60226612 D1 DE60226612 D1 DE 60226612D1
Authority
DE
Germany
Prior art keywords
autologic
cell vaccine
vaccine materials
cell
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60226612T
Other languages
English (en)
Inventor
Jingwu Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Opexa Pharmaceuticals Inc
Original Assignee
Baylor College of Medicine
Opexa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, Opexa Pharmaceuticals Inc filed Critical Baylor College of Medicine
Application granted granted Critical
Publication of DE60226612D1 publication Critical patent/DE60226612D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
DE60226612T 2001-09-14 2002-09-12 Autologe t-zell-vakzinmaterialien und verfahren Expired - Lifetime DE60226612D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/952,532 US7658926B2 (en) 2001-09-14 2001-09-14 Autologous T-cell vaccines materials and methods
PCT/US2002/028874 WO2003024393A2 (en) 2001-09-14 2002-09-12 Autologous t-cell vaccines materials and method

Publications (1)

Publication Number Publication Date
DE60226612D1 true DE60226612D1 (de) 2008-06-26

Family

ID=25492995

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60226612T Expired - Lifetime DE60226612D1 (de) 2001-09-14 2002-09-12 Autologe t-zell-vakzinmaterialien und verfahren

Country Status (22)

Country Link
US (2) US7658926B2 (de)
EP (3) EP1946767B1 (de)
JP (5) JP2005502721A (de)
KR (1) KR20040066787A (de)
CN (2) CN100346824C (de)
AT (1) ATE395076T1 (de)
AU (1) AU2002339914B2 (de)
BR (1) BR0212504A (de)
CA (1) CA2459969C (de)
DE (1) DE60226612D1 (de)
DK (2) DK1416956T3 (de)
ES (2) ES2306792T3 (de)
HK (1) HK1071698A1 (de)
HU (1) HUP0401519A3 (de)
IL (2) IL159998A0 (de)
MX (1) MXPA04001862A (de)
NZ (1) NZ530762A (de)
PL (1) PL210442B1 (de)
PT (2) PT1416956E (de)
RU (1) RU2302257C2 (de)
WO (1) WO2003024393A2 (de)
ZA (1) ZA200401502B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009448A1 (en) * 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
US7658926B2 (en) 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US7744893B2 (en) * 2002-06-05 2010-06-29 Baylor College Of Medicine T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
CN100567987C (zh) * 2002-08-08 2009-12-09 贝勒医学院 T细胞疫苗及其制备方法
EP1583823A4 (de) * 2002-12-31 2006-02-22 Baylor College Medicine Isolierung und identifizierung kreuzreaktiver t-zellen
CN1893971A (zh) * 2003-10-17 2007-01-10 贝勒医学院 用于增强cd8+细胞毒性t细胞应答和用于治疗多发性硬化的方法
PL2420833T3 (pl) * 2006-05-05 2016-03-31 Opexa Therapeutics Szczepionka z komórek T
WO2010000730A1 (en) 2008-06-30 2010-01-07 Universitätsklinikum Heidelberg Immunosuppressive blood cells and methods of producing same
WO2016037123A2 (en) * 2014-09-05 2016-03-10 Opexa Therapeutics, Inc. Compositions and methods for treating b cell mediated autoimmune disorders
CN109125717B (zh) * 2017-09-08 2022-02-22 江苏苏博生物医学股份有限公司 一种治疗慢性病的自体全细胞疫苗配方及其制备方法
US20210061875A1 (en) 2017-12-29 2021-03-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions and methods for treating autoimmune disease

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4608365A (en) * 1984-03-30 1986-08-26 University Of Southern California Treatment of neurologic functions
US4677061A (en) * 1984-10-19 1987-06-30 Genetic Systems Corporation T-cell lymphocyte subset monitoring of immunologic disease
US4898857A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Treating control nervous system diseases
US4902680A (en) * 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
US4898856A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Method for treating central nervous system diseases
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
CA1296622C (en) * 1986-08-12 1992-03-03 Jeffrey E. Anderson Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5039660A (en) * 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US6007815A (en) * 1989-03-21 1999-12-28 The Immune Response Corporation Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5861164A (en) * 1989-03-21 1999-01-19 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6221352B1 (en) * 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US5837246A (en) * 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
IL165071A (en) 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
AU8407091A (en) * 1990-07-06 1992-02-04 Allergene, Inc. Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5298386A (en) * 1992-06-09 1994-03-29 Eastman Kodak Company In-line solvent incorporation for amorphous particle dispersions
US5545716A (en) * 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
WO1994020120A1 (en) * 1993-03-12 1994-09-15 Cellcor, Inc. In vitro assay measuring degree of activation of immune cells
US5494899A (en) * 1993-04-07 1996-02-27 Oklahoma Medical Research Foundation Selective regulation of B lymphocyte precursors by hormones
AU6376194A (en) * 1993-05-14 1994-12-12 Dr. L. Willems-Instituut Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6410518B1 (en) * 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5723503A (en) * 1994-09-28 1998-03-03 Thomas Jefferson University Biological treatment for rheumatoid arthritis
US6033661A (en) * 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
US5674487A (en) * 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
US6096314A (en) * 1994-10-07 2000-08-01 Yeda Research And Development Co. Ltd. Peptides and pharmaceutical compositions comprising them
AU721898B2 (en) * 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5869057A (en) * 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
SE9502921D0 (sv) * 1995-08-23 1995-08-23 Astra Ab New compounds
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
US5750356A (en) * 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5849886A (en) * 1996-07-10 1998-12-15 Oy Aboatech Ab Extraction of myelin basic protein
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6054292A (en) * 1997-07-18 2000-04-25 Incyte Pharmaceuticals, Inc. T-cell receptor protein
US20020009448A1 (en) 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
AU5906099A (en) 1998-09-04 2000-03-27 Baylor College Of Medicine T cell peptides as therapeutics for immune-related disease
EP1159457B1 (de) * 1999-02-23 2010-11-03 Baylor College Of Medicine T-ZELLREZEPTOR Vb-Db-Jb-SEQUENZ UND VERFAHREN FÜR IHREN NACHWEIS
US6187750B1 (en) * 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
IL154544A0 (en) 2000-08-22 2003-09-17 Baylor College Medicine T CELL RECEPTOR Vbeta-Dbeta-Jbeta SEQUENCE AND METHODS FOR ITS DETECTION
US7658926B2 (en) 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US20030153073A1 (en) * 2001-11-07 2003-08-14 Paul Rogers Expansion of T cells in vitro and expanded T cell populations
DE10224223A1 (de) * 2002-05-31 2003-12-11 Mann & Hummel Filter Filterelement, insbesondere zur Flüssigkeitsfilterung aus einem Gasstrom

Also Published As

Publication number Publication date
JP2005502721A (ja) 2005-01-27
HUP0401519A2 (hu) 2004-11-29
EP1946767B1 (de) 2013-12-04
JP2016188238A (ja) 2016-11-04
PT1416956E (pt) 2008-08-26
WO2003024393A3 (en) 2003-11-06
CN101229370A (zh) 2008-07-30
CN1553812A (zh) 2004-12-08
JP4889581B2 (ja) 2012-03-07
NZ530762A (en) 2005-10-28
KR20040066787A (ko) 2004-07-27
CN101229370B (zh) 2015-09-02
RU2302257C2 (ru) 2007-07-10
JP2007254492A (ja) 2007-10-04
EP1946767A2 (de) 2008-07-23
DK1416956T3 (da) 2008-09-01
ES2418529T3 (es) 2013-08-14
EP1946767A3 (de) 2008-07-30
PL367306A1 (en) 2005-02-21
ES2306792T3 (es) 2008-11-16
IL196900A0 (en) 2011-07-31
BR0212504A (pt) 2004-08-24
HK1071698A1 (en) 2005-07-29
EP1416956B1 (de) 2008-05-14
IL159998A0 (en) 2004-06-20
EP1416956A4 (de) 2004-10-13
WO2003024393A2 (en) 2003-03-27
RU2004103626A (ru) 2005-03-27
US7658926B2 (en) 2010-02-09
JP2011168618A (ja) 2011-09-01
EP2335720B1 (de) 2013-04-03
IL196900A (en) 2015-03-31
HUP0401519A3 (en) 2009-04-28
PT2335720E (pt) 2013-07-08
US20030091578A1 (en) 2003-05-15
PL210442B1 (pl) 2012-01-31
EP1416956A2 (de) 2004-05-12
EP2335720A1 (de) 2011-06-22
CA2459969A1 (en) 2003-03-27
CN100346824C (zh) 2007-11-07
JP2015017129A (ja) 2015-01-29
MXPA04001862A (es) 2005-03-07
ATE395076T1 (de) 2008-05-15
US20050186192A1 (en) 2005-08-25
AU2002339914B2 (en) 2005-03-24
CA2459969C (en) 2014-12-02
DK2335720T3 (da) 2013-07-08
ZA200401502B (en) 2005-01-26

Similar Documents

Publication Publication Date Title
HK1071698A1 (en) Autologous t-cell vaccines materials and method
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DE60334995D1 (de) Verfahren zur herstellung von amorphen und keramischen stoffen mittels schmelzspinnen
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
DE60140259D1 (de) Antikörper gegen tnf, zusammensetzungen, verfahren und verwendungen
HUP0300369A2 (hu) Többértékű antitestek és alkalmazásuk
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
HK1087018A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
DE60123308D1 (de) Glaswerkstoff, glaskeramisches Produkt, und Verfahren zur Herstellung des Glaswerkstoffes
ATE393775T1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
ATE430160T1 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
HK1087417A1 (en) Method and apparatus for continuous large-scale radiolabeling of proteins
ATE557040T1 (de) Rekombinante antikörper sowie zusammensetzungen und verfahren zu deren herstellung und verwendung
DE60334839D1 (de) Hybridpolymerase-verfahren und -zusammensetzungen
ATE391775T1 (de) Verfahren zur herstellung oberflächenmodifizierte trägermaterialien zur bindung biologischer materialien
ATE346084T1 (de) Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga
DE69534635D1 (de) Verfahren zur produktion von verstärkt antigen wirkenden heliobacter sp. und vakzine die diesen enthalten
DE60228759D1 (de) Verfahren zur herstellung von sojazuckern und davon abgeleitetes produkt
ATE334262T1 (de) Fugenverschluss zwischen einer schiene und einer pflastereindeckung und verfahren zur herstellung
ATE359811T1 (de) Verwendung von trehalose produzierenden prokaryotischen zellen als impfstoffe
DE3581679D1 (de) Mauerstein fuer die errichtung von aufgehendem mauerwerk, sowie verfahren und vorrichtung zur herstellung solcher mauersteine.
ATE302186T1 (de) Derivate von 3-phenyl-2, 6-dioxopiperidin-3-yl propionamide und verfahren zur deren herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition